Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors

Molecular Cancer Research

Volumn 12, Issue 6, 2014, Pages 901-911

  Li, Qin ^a,b   Zhang, Yun ^a   El Naggar, Adel K ^a   Xiong, Shunbin ^a   Yang, Peirong ^a   Jackson, James G ^a   Chau, Gilda ^a   Lozano, Guillermina ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; TAMOXIFEN; MDM2 PROTEIN, MOUSE;

ANGIOSARCOMA; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL PROLIFERATION; DNA DAMAGE; GENE OVEREXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SPINDLE CELL SARCOMA; TUMOR REGRESSION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL GROWTH; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TRANSCRIPTION INITIATION; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HEMANGIOSARCOMA; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84902655791     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0089     Document Type: Article

References (37)

1. Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol 2011;8:25-37.
2. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994;86:1458-62. (Pubitemid 24317587)
3. Cai DW, Mukhopadhyay T, Liu Y, Fujiwara T, Roth JA. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gene Ther 1993;4:617-24. (Pubitemid 24305758)
4. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996;2:985-91. (Pubitemid 26306836)
5. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006;127:1323-34. (Pubitemid 44960417)
6. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007;445:661-5. (Pubitemid 46232887)
7. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:656-60. (Pubitemid 46232886)
8. Wang Y, Suh YA, Fuller MY, Jackson JG, Xiong S, Terzian T, et al. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest 2011;121:893-904.
9. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006;6:909-23. (Pubitemid 44862676)
10. Li Q, Lozano G. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res 2013;19:34-41.
11. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 2006;13:927-34.
12. Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 2010;24:1580-9.
13. Alazzouzi H, Suriano G, Guerra A, Plaja A, Espin E, Armengol M, et al. Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells. J Med Genet 2007;44:75-80. (Pubitemid 46142843)
14. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, et al. TheMDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994;84:3158-65.
15. Jiao YF, Nakamura S, Sugai T, Habano W, Uesugi N, Oikawa M, et al. p53 gene mutation and MDM2 overexpression in a case of primary malignant fibrous histiocytoma of the jejunum. APMIS. 2002;110:165-71. (Pubitemid 34327155)
16. Ganly I, Soutar DS, Brown R, Kaye SB. p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy. Br J Cancer 2000;82:392-8. (Pubitemid 30045387)
17. Li XJ, Murai M, Koyama T, Wang DY, Hashimoto K. MDM2 overexpression with alteration of the p53 protein and gene status in oral carcinogenesis. Jpn J Cancer Res 2000;91:492-8. (Pubitemid 30392319)
18. Gunther T, Schneider-Stock R, Hackel C, Kasper HU, Pross M, Hackelsberger A, et al. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations. Mod Pathol 2000;13:621-6. (Pubitemid 30436797)
19. Ohnstad HO, Castro R, Sun J, Heintz KM, Vassilev LT, Bjerkehagen B, et al. Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma. Cancer 2013;119:1013-22.
20. Eischen CM, Roussel MF, Korsmeyer SJ, Cleveland JL. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol 2001;21:7653-62. (Pubitemid 32988776)
21. Gorgoulis VG, Zacharatos P, Kotsinas A, Mariatos G, Liloglou T, Vogiatzi T, et al. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs). Mol Med 2000;6:208-37.
22. Burton EC, Lamborn KR, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J, et al. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 2002;8:180-7. (Pubitemid 34101475)
23. Gorgoulis VG, Zoumpourlis V, Rassidakis GZ, Karameris A, Rassidakis AN, Spandidos DA, et al. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. J Pathol 1996;180:129-37. (Pubitemid 26370176)
24. Marks DI, Vonderheid EC, Kurz BW, Bigler RD, Sinha K, Morgan DA, et al. Analysis of p53 and mdm-2 expression in 18 patients with Sezary syndrome. Br J Haematol 1996;92:890-9.
25. Jablkowski M, Bocian A, Bialkowska J, Bartkowiak J. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma. J Exp Clinical Cancer Res 2005;24:117-25. (Pubitemid 40655872)
26. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A 1998;95:15608-12. (Pubitemid 29018747)
27. Onel K, Cordon-Cardo C. MDM2 and prognosis. Mol Cancer Res 2004;2:1-8. (Pubitemid 38167102)
28. Forslund A, Zeng Z, Qin LX, Rosenberg S, Ndubuisi M, Pincas H, et al. MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers. Mol Cancer Res 2008;6:205-11. (Pubitemid 351342408)
29. Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol 2002;244:305-18. (Pubitemid 34450645)
30. Bearss DJ, Subler MA, Hundley JE, Troyer DA, Salinas RA, Windle JJ. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors. Oncogene 2000;19:1114-22. (Pubitemid 30153798)
31. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004;119:861-72. (Pubitemid 40017691)
32. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, Lozano G. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 2001;20:4041-9. (Pubitemid 32681609)
33. Terzian T, Wang Y, Van Pelt CS, Box NF, Travis EL, Lozano G. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol 2007;27:5479-85. (Pubitemid 47124400)
34. Barboza JA, Iwakuma T, Terzian T, El-Naggar AK, Lozano G. Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res 2008;6:947-54.
35. McDonnell TJ, Montes de Oca Luna R, Cho S, Amelse LL, Chavez-Reyes A, Lozano G. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J Pathol 1999;188:322-8. (Pubitemid 29317778)
36. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW.Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602. (Pubitemid 27152402)
37. Jackson JG, Post SM, Lozano G. Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. J Pathol 2011;223:127-36.